SABS logo

SAB BIOTHERAPEUTICS INC

SABSNASDAQ
🏆 #3405 by market capUS Equity
$336.01▼ $18.41 (−5.48%)
Simulated price
🔔
Track SABS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.5%
7d▲ 9811.8%
14d▲ 9826.4%
30d▲ 8956.9%
ytd▲ 8908.3%
1y▲ 17220.1%
🏦Market Cap
$293M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
226.3x
Expensive
Otter Score
48
Weak

Trading Snapshot

Day Range
$332.21 – $341.94
52-Week Range
$1.85 – $5.15
Volume
$4.58B
Avg Volume
$3.19B
Shares Outstanding
76.5M
Next Earnings
Nov 17, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$295,644
P/E Ratio
22.6
P/S Ratio
226.3x
EPS (TTM)
$-1.42
Dividend Yield
—

Why Investors Own SABS

  • ✓High-growth profile — revenue up -8.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 45% gross margin and 19% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SABS logo

SAB BIOTHERAPEUTICS INC

SABS
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$1M▼ −8.9% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
45.3%▲ +3.8% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$184,854▼ −8.9% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$244,317▼ −8.9% YoY
StockOtter · stockotter.space

About SAB BIOTHERAPEUTICS INC

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Price Target

ⓘ
Average Target
$373.08
▲ +11.0% Upside
High Target$456.22
Low Target$289.97
Based on 39 analysts

Latest News & Updates

🚀
CNBC·2h ago

SAB BIOTHERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift SABS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

SAB BIOTHERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.